Ekso Bionics Holdings, Inc.
NASDAQ:EKSO · NASDAQ Capital Market
+$2.84 today
Vol 0.13M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-129.6%
avg -242.5%
ROIC
-87.8%
avg -98.1%
ROA
-58.2%
avg -66.2%
Analysis
ROA is currently the strongest return metric at -58.2% versus its period average of -66.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Scott G. Davis | Chief Executive Officer & Director | $488,750.00 | — | 55 | $78,777.00 | 3.25% |
Jason C. Jones | Chief Operating Officer | $389,250.00 | — | — | $4,449.00 | 0.18% |
Jerome Wong | Chief Financial Officer & Corporate Secretary | $389,250.00 | — | 51 | $4,184.00 | 0.17% |
Katherine Strausser | Principal Controls Engineer | — | — | — | — | — |
Ann Cookson | Human Resources Director | — | — | — | $456,707.00 | 18.83% |
Stephan Aderhold | Senior Vice President & GM of EMEA | — | — | — | — | — |
Lisa Bentley | Head of Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$1.20M
Sells
6
$232,062.40
Net Sentiment
+$971,688.87
Net buying
Most Active
ASHER DANIEL
10 transactions
1–10 of 18
Analysis
Insiders reported 12 buys worth $1.20M and 6 sells worth $232,062.40 over the last 12 months. That adds up to net buying of $971,688.87. ASHER DANIEL was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +62.7% | +8.9% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +62.7% over three years. Forward estimates point to Revenue at +8.9% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Adlai Nortye Ltd.
NASDAQ:ANL
$536.11M
Aytu BioPharma, Inc.
AYTU
$18.71M
OSR Holdings, Inc.
OSRH
$9.63M
Allurion Technologies Inc.
ALUR
$4.38M
Co-Diagnostics, Inc.
CODX
$3.76M
Ernexa Therapeutics Inc.
ERNA
$1.95M
Aethlon Medical, Inc.
AEMD
$1.44M
GeoVax Labs, Inc.
GOVX
$1.28M
ProPhase Labs, Inc.
PRPH
$355,276.00
enVVeno Medical Corporation
NVNO
$165,030.00
Who manages EKSO?
Ekso Bionics Holdings, Inc. (EKSO) lists 7 active executives. The top listed executive is Katherine Strausser, Principal Controls Engineer.
Are EKSO insiders buying or selling?
Recent insider activity shows net buying of $5.62M.
Explore More
Continue the stock analysis
Jump to another research area for this company.